Pharmala Biotech Holdings Inc. MDXXF

MDXXF Company Overview

PharmAla Biotech Holdings Inc. is a Canadian life sciences company focused on the research, development, and commercialization of pharmaceutical-grade psychedelic compounds, primarily MDMA (3,4‑methylenedioxymethamphetamine). The company operates within the biopharmaceutical and psychedelic therapeutics industries, supplying regulated active pharmaceutical ingredients (APIs) intended for clinical research, drug development, and potential commercial therapeutic use.

The company’s core business centers on the development and sale of LaNeo™ MDMA, a standardized, GMP-compliant MDMA API designed for use in regulated clinical trials and pharmaceutical applications. PharmAla primarily serves biotechnology companies, academic institutions, and clinical research organizations developing MDMA-assisted therapies, particularly for mental health and neurological conditions. Founded in 2020, the company was established to address the lack of legally compliant, pharmaceutical-grade MDMA available to researchers and has since positioned itself as a specialized supplier in a tightly regulated niche of the emerging psychedelic medicine market.